BCR and acute lymphoblastic leukemia: On the other hand, although the third-generation TKI ponatinib is one of the newest treatments and has demonstrated potent activity in both wild-type BCR/ABL1-positive ALL and resistant variants, it is also associated with an increased risk of thrombosis and pancreatitis in children [93].